UY32360A - Compuestos de etanamina y métodos de utilización de los mismos 545 - Google Patents
Compuestos de etanamina y métodos de utilización de los mismos 545Info
- Publication number
- UY32360A UY32360A UY0001032360A UY32360A UY32360A UY 32360 A UY32360 A UY 32360A UY 0001032360 A UY0001032360 A UY 0001032360A UY 32360 A UY32360 A UY 32360A UY 32360 A UY32360 A UY 32360A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- same
- ethanamine
- compounds
- ethanamine compounds
- Prior art date
Links
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 title abstract 2
- -1 ethanamine compound Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Confectionery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14067308P | 2008-12-24 | 2008-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY32360A true UY32360A (es) | 2010-07-30 |
Family
ID=42288011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001032360A UY32360A (es) | 2008-12-24 | 2009-12-23 | Compuestos de etanamina y métodos de utilización de los mismos 545 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8013165B2 (enExample) |
| EP (2) | EP2610246A1 (enExample) |
| JP (1) | JP5491524B2 (enExample) |
| KR (1) | KR20110097996A (enExample) |
| CN (1) | CN102333762B (enExample) |
| AR (1) | AR074981A1 (enExample) |
| AU (1) | AU2009330745B2 (enExample) |
| BR (1) | BRPI0923476A2 (enExample) |
| CA (1) | CA2748235A1 (enExample) |
| CL (1) | CL2011001590A1 (enExample) |
| CO (1) | CO6450688A2 (enExample) |
| CR (1) | CR20110365A (enExample) |
| CU (1) | CU24017B1 (enExample) |
| DO (1) | DOP2011000205A (enExample) |
| EA (1) | EA201190064A1 (enExample) |
| EC (1) | ECSP11011161A (enExample) |
| GT (1) | GT201100186A (enExample) |
| HN (1) | HN2011001773A (enExample) |
| IL (1) | IL213518A0 (enExample) |
| MX (1) | MX2011006680A (enExample) |
| NI (1) | NI201100131A (enExample) |
| NZ (1) | NZ593282A (enExample) |
| PE (1) | PE20120249A1 (enExample) |
| SA (1) | SA109310013B1 (enExample) |
| SG (2) | SG192510A1 (enExample) |
| SV (1) | SV2011003962A (enExample) |
| TW (1) | TWI442922B (enExample) |
| UA (1) | UA106056C2 (enExample) |
| UY (1) | UY32360A (enExample) |
| WO (1) | WO2010074647A1 (enExample) |
| ZA (1) | ZA201105441B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923476A2 (pt) * | 2008-12-24 | 2016-01-19 | Astrazeneca Ab | composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica |
| CN112250676B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氧杂环化合物 |
| CN112279843B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氮杂环化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3422191A (en) | 1965-01-21 | 1969-01-14 | Synergistics Inc | Compositions and methods for tranquilization employing salts of n-morpholine ethanol |
| GB1427026A (en) | 1972-11-20 | 1976-03-03 | Ici Ltd | Synthetic film materials |
| JPS5756474B2 (enExample) | 1973-05-26 | 1982-11-30 | ||
| GB9320273D0 (en) | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| US5455259A (en) | 1987-02-06 | 1995-10-03 | Fisons Corporation | Compounds for the treatment of neurodegenerative disorders |
| SG52662A1 (en) | 1988-08-12 | 1998-09-28 | Astra Ab | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
| JP2514855B2 (ja) | 1990-08-08 | 1996-07-10 | キッセイ薬品工業株式会社 | 光学活性なアラニンアニリド誘導体の酸付加塩 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| PT612314E (pt) * | 1991-10-30 | 2000-06-30 | Astra Ab | Derivados de etilamina 2-heterociclicos e seu uso como produtos farmaceuticos |
| AU3897693A (en) | 1992-04-03 | 1993-11-08 | Astra Aktiebolag | Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders |
| EP0898566B1 (en) * | 1996-04-19 | 2002-11-06 | Akzo Nobel N.V. | Substituted benzylamines and their use for the treatment of depression |
| EP0869122B1 (en) | 1997-03-31 | 2002-12-04 | Korea Research Institute Of Chemical Technology | Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| BRPI0923476A2 (pt) * | 2008-12-24 | 2016-01-19 | Astrazeneca Ab | composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica |
-
2009
- 2009-12-22 BR BRPI0923476A patent/BRPI0923476A2/pt not_active IP Right Cessation
- 2009-12-22 PE PE2011001282A patent/PE20120249A1/es not_active Application Discontinuation
- 2009-12-22 SG SG2013053749A patent/SG192510A1/en unknown
- 2009-12-22 SG SG2011040342A patent/SG171928A1/en unknown
- 2009-12-22 AU AU2009330745A patent/AU2009330745B2/en not_active Ceased
- 2009-12-22 SA SA109310013A patent/SA109310013B1/ar unknown
- 2009-12-22 US US12/644,046 patent/US8013165B2/en not_active Expired - Fee Related
- 2009-12-22 UA UAA201107171A patent/UA106056C2/uk unknown
- 2009-12-22 NZ NZ593282A patent/NZ593282A/xx not_active IP Right Cessation
- 2009-12-22 EP EP13159532.4A patent/EP2610246A1/en not_active Withdrawn
- 2009-12-22 EA EA201190064A patent/EA201190064A1/ru unknown
- 2009-12-22 EP EP09835355A patent/EP2391606A4/en not_active Withdrawn
- 2009-12-22 CN CN200980157411.9A patent/CN102333762B/zh not_active Expired - Fee Related
- 2009-12-22 CA CA2748235A patent/CA2748235A1/en not_active Abandoned
- 2009-12-22 KR KR1020117017236A patent/KR20110097996A/ko not_active Withdrawn
- 2009-12-22 WO PCT/SE2009/051493 patent/WO2010074647A1/en not_active Ceased
- 2009-12-22 JP JP2011543474A patent/JP5491524B2/ja not_active Expired - Fee Related
- 2009-12-22 MX MX2011006680A patent/MX2011006680A/es active IP Right Grant
- 2009-12-23 UY UY0001032360A patent/UY32360A/es not_active Application Discontinuation
- 2009-12-23 AR ARP090105104A patent/AR074981A1/es not_active Application Discontinuation
- 2009-12-23 TW TW098144591A patent/TWI442922B/zh not_active IP Right Cessation
-
2011
- 2011-06-13 IL IL213518A patent/IL213518A0/en unknown
- 2011-06-24 SV SV2011003962A patent/SV2011003962A/es unknown
- 2011-06-24 CL CL2011001590A patent/CL2011001590A1/es unknown
- 2011-06-24 EC EC2011011161A patent/ECSP11011161A/es unknown
- 2011-06-24 NI NI201100131A patent/NI201100131A/es unknown
- 2011-06-24 HN HN2011001773A patent/HN2011001773A/es unknown
- 2011-06-24 CU CU2011000141A patent/CU24017B1/es not_active IP Right Cessation
- 2011-06-24 CR CR20110365A patent/CR20110365A/es unknown
- 2011-06-24 GT GT201100186A patent/GT201100186A/es unknown
- 2011-06-24 DO DO2011000205A patent/DOP2011000205A/es unknown
- 2011-06-29 CO CO11081454A patent/CO6450688A2/es not_active Application Discontinuation
- 2011-07-22 ZA ZA2011/05441A patent/ZA201105441B/en unknown
- 2011-08-29 US US13/219,892 patent/US20120115913A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,303 patent/US20120277272A1/en not_active Abandoned
-
2013
- 2013-01-24 US US13/748,852 patent/US9035065B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CR11861A (es) | Compuestos organicos | |
| CO6351738A2 (es) | Compuestos organicos | |
| CY1117143T1 (el) | Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης | |
| EA201170772A1 (ru) | Органические соединения | |
| CR11251A (es) | Depsipeptidos ciclicos y usos de los mismos | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| SV2011003855A (es) | Heteroarilos sustituidos | |
| ECSP11011411A (es) | Derivados de prolina como inhibidores de catepsina | |
| CR20120264A (es) | Compuestos | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| BR112012011328A2 (pt) | inibidores de akt | |
| GT200900309A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
| CR10243A (es) | "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos" | |
| PA8855001A1 (es) | Monocarbamas | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| EA201001855A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
| UY32042A (es) | Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90 | |
| DOP2009000214A (es) | Macrolidos basados en eritromicina | |
| ATE533477T1 (de) | Pharmazeutische zusammensetzungen enthaltend irbesartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20190121 |